Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b

DiLorenzo, P.A.; Goodman, Neal; Lansville, Frank; Markel, William M.

doi:10.1016/s0190-9622(09)80237-5

Cited by 10 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, intralesional IFNa-2b is an important alternative to consider for treatment of nonmelanoma skin cancers for which surgery would be deforming or would destroy function. DiLorenzo et al 4 reported the successful treatment of an invasive recurrent BCC involving the intraorbital structures and frontal bone. In our own series, patient 6 would 8 Lesions that are extremely large and less amenable for excision may be reduced in size by initial treatment with IFN.…”

Section: Discussionmentioning

confidence: 99%

“…In the United States, IFNα‐2b has been approved for the treatment of chronic hepatitis B and hepatitis C, hairy cell leukemia, AIDS‐related Kaposi's sarcoma, chronic myelogenous leukemia, malignant melanoma, follicular lymphoma, and condylomata acuminata. In addition, the efficacy of IFNα‐2b has been demonstrated in the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) 2–10 …”

mentioning

confidence: 99%

“…In addition, the efficacy of IFNa-2b has been demonstrated in the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). [2][3][4][5][6][7][8][9][10]…”

mentioning

confidence: 99%

See 2 more Smart Citations

Intralesional Interferon alpha-2b in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma: Revisited

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Intralesional Interferon alpha-2b in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma: Revisited

et al. 2004

View full text Add to dashboard Cite

show abstract

“…DiLorenzo et al . reported a case of invasive BCC of the orbit and frontal bone, recalcitrant to radiation, excision, cryosurgery and electrodessication and curettage 140 with a complete response and disease‐free status after 16 months of follow up. For the treatment of SCC, IFN α‐2b has shown promise in several studies, 141,142 although long‐term data are lacking.…”

Section: Traditional Non‐surgical Therapiesmentioning

confidence: 99%

Non-surgical treatments of primary, non-melanoma eyelid malignancies: a review

Murchison

Walrath

Washington

2011

Clinical &Amp; Experimental Ophthalmology

View full text Add to dashboard Cite

The diagnosis and management of periocular cutaneous malignancies are essential components of an ophthalmologist's practice. Skin cancers comprise nearly one-third of newly diagnosed malignancies. Furthermore, the incidence of skin cancer appears to be increasing. Multiple treatment modalities exist for periocular cutaneous malignancy. Surgical extirpation, often with the combined expertise of a Mohs micrographic surgeon, is typically the first line therapy and is often curative in the periocular region, depending on a variety of factors, including tumour histology, specific location, depth of invasion and surgical technique. However, there are instances where a less invasive, non-surgical treatment option is warranted, including patients who are poor surgical risks or those with diffuse disease. The purpose of this article is to review the literature and describe the non-surgical treatment options, indications and efficacies for non-melanoma primary eyelid malignancies.

show abstract

“…Lippmann et al berichten nach Einsatz von IFN-α in Kombination mit 13-cis-Retinsäure (1 mg/kg KG) von 25% kompletten Remissionen bei inoperablen Spinaliomen (SCC; 7/19) [60]. Weitere Einzelfallbeschreibungen und Untersuchungen bestätigen diese Daten bezüglich der BCC [1,13,15,26]. Weitere Einzelfallbeschreibungen und Untersuchungen bestätigen diese Daten bezüglich der BCC [1,13,15,26].…”

Section: Spinaliome Und Basalzellkarzinomeunclassified

Zytokine

Nashan¹,

Luger²

2001

Der Hautarzt

View full text Add to dashboard Cite

Various therapeutic options using cytokines have been described in the treatment of melanoma, T cell lymphoma, B cell lymphoma, squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. The treatment regimens include cytokine substitution, cytokine induction, cytokine transfection and therapeutic cytokine constructs. In the adjuvant treatment of melanomas, IFN-alpha has become well established. Statistical evaluations of different adjuvant trials show that a significant prolongation of recurrence-free intervals can be achieved. IL-2 has a role in the therapy of advanced melanomas as well as in vaccination strategies. Further possible therapeutic immune modulations, which have been evaluated in experimental approaches and pilot studies, include treatment with IL-4, IL-7 and GM-CSF. Treatment with IL-12 promises to open new perspectives. A well established regimen in the treatment of T cell lymphoma stages Ia-IIb is the combination of PUVA and IFN-alpha. In vitro data also indicate an important (patho)physiological role for IL-12, so that this agent has been tested in phase I studies. IL-2, IFN-gamma, and the fused cytokine-toxin molecules DAB389IL-2 offer further therapeutic alternatives. B cell lymphomas are treated with antibody-IL-2 fusion proteins. Advanced or inoperable squamous cell carcinoma and basal cell carcinoma may be treated with local IFN-alpha injections. IFN-alpha or TNF-alpha may be considered for the treatment of recurrent or advanced Merkel cell carcinoma. In dermatological oncology cytokine treatment focuses on melanome an T cell lymphome. Cytokine application is mainly an integral part of multimodal regimens.

show abstract

Regional and intralesional treatment of invasive basal cell carcinoma with interferon alfa-n2b

Cited by 10 publications

References 14 publications

Intralesional Interferon alpha-2b in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma: Revisited

Intralesional Interferon alpha-2b in the Treatment of Basal Cell Carcinoma and Squamous Cell Carcinoma: Revisited

Non-surgical treatments of primary, non-melanoma eyelid malignancies: a review

Zytokine

Contact Info

Product

Resources

About